Here’s How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 Years
Madrigal Pharmaceuticals (NASDAQ:MDGL) has outperformed the market over the past 5 years by 14.88% on an annualized basis…
Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022, with new traders looking for the next huge move.
High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,800 Today
Madrigal Pharmaceuticals (NASDAQ:MDGL) has outperformed the market over the past 5 years by 15.43% on an annualized basis…
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.
Madrigal Pharmaceuticals Announces $300M In Financing Events To Advance Resmetirom Program
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. JMP has…
Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom.
Madrigal Pharmaceuticals shares jumped 268.1% to close at $234.83 on Monday and gained 4.4% to trade at $245.26 on Tuesday.
Peering Into Madrigal Pharmaceuticals’s Recent Short Interest
Madrigal Pharmaceuticals's (NASDAQ:MDGL) short percent of float has risen 3.82% since its last report. The company recently reported that it has 2.16 million shares sold short, which is 15.49% of all regular shares that are available for trading.
HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $225
HC Wainwright & Co. analyst Ed Arce maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $170 to $225.
Analyst Ratings for Madrigal Pharmaceuticals
Madrigal Pharmaceuticals (NASDAQ:MDGL) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…